{"created":"2021-03-01T07:25:13.379929+00:00","id":45415,"links":{},"metadata":{"_buckets":{"deposit":"ea01c1c9-67c5-46b3-8138-0b1d3e54cdaf"},"_deposit":{"id":"45415","owners":[],"pid":{"revision_id":0,"type":"depid","value":"45415"},"status":"published"},"_oai":{"id":"oai:tsukuba.repo.nii.ac.jp:00045415","sets":["3:62:5298:5437"]},"item_5_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2017-12","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"41","bibliographicPageStart":"35","bibliographicVolumeNumber":" 12","bibliographic_titles":[{"bibliographic_title":" Clinical ophthalmology  "}]}]},"item_5_creator_3":{"attribute_name":"著者別名","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"五所, 正彦"}],"nameIdentifiers":[{},{},{}]}]},"item_5_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Purpose: Tranexamic acid (TXA) is a widely used antifibrinolytic agent that can also cause a decrease in vascular permeability. We hypothesized that TXA could improve macular edema (ME) that is caused by an increase in retinal vascular permeability. The aim of this study is to evaluate the efficacy of oral TXA for ME associated with retinal vein occlusion (RVO) or diabetic ME (DME).\n\nPatients and methods: Oral TXA (1,500 mg daily for 2 weeks) was administered to patients with persistent ME secondary to RVO (7 eyes) and DME (7 eyes). After 2 weeks (ie, the final day of administration) and 6 weeks (ie, 4 weeks after the final administration), best-corrected visual acuity and central macular thickness (CMT) were measured and compared with baseline. Analyses were performed for RVO and DME cases. No other treatment was performed during the study period.\n\nResults: In RVO cases, significant improvement in CMT was found between baseline (467.7±121.4 µm) and 2-week measurements after treatment (428.7±110.5 µm, p=0.024). No significant change was found in CMT between measurements taken at baseline and 6 weeks after treatment. In DME cases, no significant change was found in CMT between measurements taken at baseline and 2 or 6 weeks after treatment. In all analyses of best-corrected visual acuity, no significant change was observed.\nConclusion: The results support the hypothesis that plasmin plays a role in the development of ME associated with RVO, and oral TXA administration may be useful as an adjuvant treatment when combined with other agents such as anti-vascular endothelial growth factor.","subitem_description_type":"Abstract"}]},"item_5_publisher_27":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Dove Medical Press"}]},"item_5_relation_10":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"29339919 ","subitem_relation_type_select":"PMID"}}]},"item_5_relation_11":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"10.2147/OPTH.S149935","subitem_relation_type_select":"DOI"}}]},"item_5_rights_12":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© 2018 Takeyama et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php)."}]},"item_5_select_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"publisher"}]},"item_5_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1177-5483","subitem_source_identifier_type":"ISSN"}]},"item_5_source_id_9":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA12240029 ","subitem_source_identifier_type":"NCID"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Takeyama, Masayuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Takeuchi, Fumio"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Gosho, Masahiko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Sugita, Keijiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Zako, Masahiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Iwaki, Masayoshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kamei, Motohiro"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-02-22"}],"displaytype":"detail","filename":"CO_12.pdf","filesize":[{"value":"797.1 kB"}],"format":"application/pdf","licensetype":"license_9","mimetype":"application/pdf","url":{"label":"CO_12","url":"https://tsukuba.repo.nii.ac.jp/record/45415/files/CO_12.pdf"},"version_id":"e03c11ed-2d3a-419d-a769-a80192ba0c68"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Effect of oral tranexamic acid on macular edema associated with retinal vein occlusion or diabetes","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Effect of oral tranexamic acid on macular edema associated with retinal vein occlusion or diabetes"}]},"item_type_id":"5","owner":"1","path":["3074","5437"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-02-22"},"publish_date":"2018-02-22","publish_status":"0","recid":"45415","relation_version_is_last":true,"title":["Effect of oral tranexamic acid on macular edema associated with retinal vein occlusion or diabetes"],"weko_creator_id":"1","weko_shared_id":5},"updated":"2022-04-27T09:17:04.205999+00:00"}